$15 billion market formed by AIDS drug maker
A market worth $15 billion has been created by Gilead Sciences Inc., the world's biggest AIDS-drug maker, by making a single pill that is to be taken every day that attacks virus with three medicines together and this has revolutionized treatment.
The success has hugely had an impact on Foster City, California-based Gilead and rivals Merck & Co. and Bristol-Myers Squibb Co.
At the moment, market has about 31 drugs that help making HIV take form of a manageable disease rather than a death sentence and this has happened three decades after the virus being discovered. After 2004, only six were approved.
George Hanna, vice president of virology for U. S. medical and HIV early development at Bristol-Myers, based in New York said, “The bar for bringing on a drug in HIV has gotten higher. You can no longer bring to market a drug you're going to have to take three times a day. All of a sudden, we're seeing a lot less in the pipeline.”
Over the years medicines that have been made have proved effective, safe and the virus has been attacked by these medicines in various ways.
New Zealand News
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- CATL and LG Energy account for nearly 54% of global xEV battery market: SNE Research
- Italian motorcycle racer Valentino Rossi enters e-bike business with VR46 MTB range
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain
- TenneT adds more electric BMWs to study use of EVs to support power grids
- Italy’s ASPI announces plans to install cross-country ultra-fast EV charging network